TGFB1 and scleroderma: That dasatinib can indeed compromise undesired effects of TGF-β in vivo was suggested by preclinical studies in an in vitro model of a fibrosing disorder in which dasatinib treatment of scleroderma and normal fibroblasts led to decreased production of extracellular matrix proteins [28].